home / stock / gnftf / gnftf news

GNFTF News and Press, Genfit Ord From 06/07/23

Stock Information
Company Name: Genfit Ord
Stock Symbol: GNFTF
Market: OTC
Website: genfit.com
Menu
GNFTF GNFTF Quote GNFTF Short GNFTF News GNFTF Articles GNFTF Message Board
Get GNFTF Alerts

News, Short Squeeze, Breakout and More Instantly...
GNFTF - GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); June 7 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with ra...
GNFTF - GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

E xclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor SRT-015 in acute liver disease Preclinical and clinical evidence support ASK1 inhibition as a relevant therapeutic strategy in ...

GNFTF - Drug pricing watchdog raises alarm over upcoming liver disease meds

2023-05-29 15:00:00 ET The Institute for Clinical and Economic Review (ICER), the influential U.S. drug pricing watchdog, has warned about the affordability of two medications currently undergoing studies for liver disease, nonalcoholic steatohepatitis (NASH). Issuing a so-called access...

GNFTF - GENFIT: May 24, 2023 Combined Shareholders Meeting results

Q uorum of 29.54 % on first convening ; allowing approval of all the resolutions recommended by the Board of Directors Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 24 , 2023 - GENFIT (...
GNFTF - GENFIT Announces Publication of the Development and Validation of NIS2+(TM) in the Journal of Hepatology

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); May 23 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with ra...

GNFTF - GENFIT Reports First Quarter 2023 Financial Information

Cash, cash equivalents and current financial assets totaled €128.6 million as of March 31, 2023 Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); May 11, 2023 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmace...

GNFTF - Genfit: Major Data Release Before End Of Q2 Of 2023 Could Get Ball Rolling

2023-05-11 16:04:46 ET Summary Results from the phase 3 ELATIVE study, using elafibranor to treat patients with primary biliary cholangitis, are expected to be released before end of Q2 of 2023. The primary biliary cholangitis market is expected to reach $1.7 billion by 2029. ...
GNFTF - GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland); May 9 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and sev...

GNFTF - GENFIT Announces Publication of Extra-Financial Performance Report 2022

GENFIT Announces Publication of Extra-Financial Performance Report 2022 Lille ( France ) ; Cambridge, ( Massachusetts, United States ) ; Zurich (Switzerland); April 2 7 , 202 3 - GENFIT (Nasdaq and Euronext: G...

GNFTF - GENFIT Annual Combined General Meeting of May 24, 2023 - Availability of Preparatory Documents

Lille ( France ) ; Cambridge ( Massachusetts, United States ) ; Zurich (Switzerland) ; April 19 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with sev...
Previous 10 Next 10